Report Overview

Indian Multiple Myeloma market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Myeloma, also known as multiple myeloma, is a type of bone marrow cancer arising from plasma cells, which are normally found in the bone marrow. Myeloma affects multiple (hence multiple myeloma) places in the body where bone marrow is normally active in adults, i.e., within the bones of the spine, skull, pelvis, the rib cage, and the areas around the shoulders and hips. Plasma cells are a type of white blood cell found in the bone marrow. They are part of the immune system and help fight infection. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 6574. The multiple myeloma market is majorly driven by high prevalence of multiple myeloma, rich promising pipeline of drugs, high diagnostics rate and vulnerable geriatric population. In addition, launches of drugs annually and advances in pharmaceuticals and biotechnological sectors or industries are some of the impacting factors that drives the market growth.



Market Growth Drivers

Significant developments in the healthcare sector, along with the increasing prevalence of haematological cancer, is one of the key factors driving the growth of the market. Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the bodys immune system to identify and attack the myeloma cells, is also providing a boost to the market growth. Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor. These medicines are used to facilitate the delivery of macromolecular agents into the bone marrow and catalyse antitumor responses. Other factors, including the rising healthcare expenditures and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.